A drop of blood could make ear surgery more precise

In surgery, precision often depends on contrast. A tumour edge, a membrane, a blood vessel or an inflamed surface becomes easier to identify when the surgeon can distinguish one tissue from another. A recent laser study takes this idea further: instead of using contrast mainly for seeing, researchers used a thin layer of blood to make difficult tissue easier to remove.

The work, led by Paula Enzian at the Medical Laser Center Lübeck, examined whether a 445 nanometre blue diode laser could more predictably ablate weakly absorbing cholesteatoma-like tissue when a fine blood layer was present. The study, published in Lasers in Surgery and Medicine and selected as the journal’s July 2026 Editor’s Choice, found that a blood layer of around 50–100 micrometres enabled measurable laser ablation where no ablation occurred without blood under the same conditions.

Cholesteatoma is an abnormal growth of keratinising squamous epithelium in the middle ear. Although non-cancerous, it can behave destructively, eroding nearby structures and threatening hearing. Surgery requires complete removal while protecting delicate anatomy, including the ossicles, the tiny bones that transmit sound. For this reason, any tool that improves controlled tissue removal without increasing collateral damage is of considerable interest. Related work from the Lübeck group has shown that 445 nm diode lasers can be used for precise cholesteatoma ablation, with optical coherence tomography used to measure ablation craters and assess tissue effects.

The physics is straightforward but clinically significant. Blue light at 445 nm is absorbed strongly by haemoglobin. This makes such lasers useful in ear, nose and throat surgery because blood-rich tissue can be cut while achieving haemostasis. The problem is that cholesteatoma tissue is often pale, weakly absorbing and strongly scattering. In such tissue, laser energy may not be deposited efficiently. Ablation can therefore be delayed, unpredictable or abrupt once carbonisation begins.

Enzian’s team tested whether blood could act as a temporary optical absorption layer. They applied controlled volumes of blood to a weakly absorbing tissue model and irradiated the samples using a 445 nm diode laser at continuous-wave powers of 1 W and 4 W. The laser fibre was held at working distances of 1 mm and 2 mm and moved across tissue at 5 mm per second. Optical coherence tomography was then used to measure the depth of ablation and the thickness of the blood layer.

The result was a demonstration of how a very small biological layer can change energy delivery. At 4 W, a blood layer of approximately 50–100 µm produced a maximum ablation depth of about 370 µm. Without blood, no ablation was achieved under the same tested conditions. The researchers also developed a theoretical model to estimate the optimal blood layer thickness, noting that the best result depends on laser power, working distance and other optical parameters.

This points towards a wider movement in surgery: moving from brute-force tissue removal towards controlled, image-informed, energy-based micro-intervention. In this context, light is not just a cutting tool. It is a controllable energy source whose interaction with tissue depends on wavelength, absorption, scattering, hydration, pigmentation and blood content.

Canada’s parallel focus: Biomedical optics

Canada is active in many adjacent areas of biomedical optics and image-guided treatment. At the University of Waterloo, Professor Kostadinka Bizheva’s Biomedical Optics Research Group develops optical coherence tomography technologies for clinical imaging, including monitoring surgical procedures involving the retina, cornea, heart and brain. OCT is valuable because it can provide non-contact, non-invasive, micrometre-scale cross-sectional images of tissue. This the form of feedback that can turn laser-tissue interaction from an empirical art into a measurable intervention.

In British Columbia, the Optical Cancer Imaging Lab at BC Cancer develops optical tools for early cancer detection and disease management, including OCT, autofluorescence and other light-based approaches for epithelial tissues. The group notes that many cancers originate in epithelial layers and that high-resolution optical imaging can reveal structural and functional changes before conventional imaging can detect early lesions. This Canadian work is not directed at cholesteatoma, but it reflects the same scientific principle: light can interrogate superficial tissue architecture with exceptional precision.

Carleton University’s Laser-Assisted Medical Physics and Engineering Laboratory also illustrates Canada’s strength in biophotonics. The laboratory develops rapid, label-free and non-invasive optical techniques, including Raman spectroscopy and coherent Raman imaging, with applications in biodosimetry, radiation research and histopathology. These approaches differ from surgical laser ablation, but they share the same translational challenge: taking optical physics and making it useful in clinical decision-making. ]

Canada’s broader medical-technology ecosystem is also pushing towards precise, non-invasive or minimally invasive tissue treatment. Sunnybrook Research Institute in Toronto has long been associated with focused ultrasound research, and its spin-off Arrayus Technologies received Health Canada approval in 2024 for an MRI-guided focused ultrasound system for ablation of uterine fibroid tissue. Unlike a blue diode laser used in middle-ear surgery, focused ultrasound uses acoustic rather than optical energy. Yet the objective is similar: deposit energy precisely, monitor therapy in real time and protect surrounding healthy tissue.

The comparison is useful because the future of surgery is likely to be multimodal. Lasers, ultrasound, robotics, endoscopy, OCT, fluorescence imaging and machine learning will increasingly converge. The surgeon of the future may not rely on a single tool but on a system that sees, models, ablates and verifies. In such a system, even a thin film of blood could become a controllable variable rather than an unpredictable nuisance.

Current limitations

The Lübeck study is a basic science investigation, not a clinical trial demonstrating improved patient outcomes. The blood layer needs to be reproducible and controllable in a real surgical field. Too little blood may fail to improve absorption; too much may shield the underlying tissue or change the ablation profile. Heat transfer, smoke generation, tissue charring and safety margins near the ossicles and facial nerve will require careful evaluation before such an approach can be adopted routinely.

Nevertheless, the idea is elegant. Rather than increasing the laser power to force ablation in pale tissue, the researchers altered the optical environment at the tissue surface. That could allow lower-power, more controlled ablation with less reliance on thermal runaway or carbonisation. In delicate anatomical sites such as the middle ear, where fractions of a millimetre matter, this is precisely the kind of refinement that can make a surgical technology clinically meaningful.

The broader lesson is that energy-based medicine is becoming more sophisticated. The key question is no longer whether light, sound or heat can destroy tissue. It is whether energy can be delivered in a way that is spatially precise, biologically predictable and compatible with functional preservation.